Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2654910 | 0.79 | CRHBP (0.39) | ERN1CYP3A4TSHRALDH1A1GAA | |
| SCHEMBL29950531 | 0.77 | BACE1 (0.41) | ERN1 | |
| SCHEMBL2170779 | 0.76 | TRIM24 (0.31) | ERN1 | |
| SCHEMBL20268024 | 0.76 | HSD17B10 (0.34) | ERN1CYP3A4TSHRALDH1A1GAA | |
| SCHEMBL29952500 | 0.76 | CYP3A4 (0.35) | CYP3A4TSHRALDH1A1GAAHSD17B10 | |
| SCHEMBL29736642 | 0.76 | HSD17B10 (0.34) | ERN1CYP3A4TSHRALDH1A1GAA | |
| SCHEMBL2226680 | 0.76 | CYP3A4 (0.35) | CYP3A4TSHRALDH1A1GAAHSD17B10 | |
| SCHEMBL1321340 | 0.76 | RRM2 (0.45) | CYP3A4TSHRALDH1A1GAAHSD17B10 | |
| SCHEMBL20917010 | 0.75 | KDM4E (0.33) | GAAKDM4EMEN1KMT2A | |
| SCHEMBL20917009 | 0.75 | KDM4E (0.33) | GAAKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120717948-A | Synthesis method of 3-bromo-6-chloropyridine-2-formaldehyde and 3-bromo-6-chloropyridine-2-formaldehyde | 上海毕得医药科技股份有限公司 | 2025-09-30 | — | — | CN | disclosed |
| CN-120717948-A | Synthesis method of 3-bromo-6-chloropyridine-2-formaldehyde and 3-bromo-6-chloropyridine-2-formaldehyde | 上海毕得医药科技股份有限公司 | 2025-09-30 | — | — | CN | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| WO-2025124496-A1 | COMPOUND CONTAINING PYRAZOLE RING AND BICYCLIC HETEROARYL GROUP, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 正大天晴药业集团股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| EP-4554680-A1 | INHIBITORS OF HPK1 AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118556059-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20240124490-A1 | INHIBITORS OF HPK1 AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2024015251-A1 | INHIBITORS OF HPK1 AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-9771370-B2 | Compounds for the inhibition of indoleamine-2,3-dioxygenase | MERCK PATENT GMBH (DE) | 2017-09-26 | — | — | US | disclosed |
| CN-107074859-A | Indoleamine 2, the diaza and three aza-tricycle compounds of the cyclohexyl-ethyl substitution of 3 dioxygenases (IDO) antagonist are used as treating cancer | 默克专利有限公司 | 2017-08-18 | — | — | CN | disclosed |
| EP-3189054-A1 | CYCLOHEXYL-ETHYL SUBSTITUTED DIAZA- AND TRIAZA-TRICYCLIC COMPOUNDS AS INDOLE-AMINE-2,3-DIOXYGENASE (IDO) ANTAGONISTS FOR THE TREATMENT OF CANCER | Merck Patent GmbH (DE) | 2017-07-12 | — | — | EP | disclosed |
| EP-3148971-A1 | DEUBIQUITINASE INHIBITORS | Pharmakea, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20170088520-A1 | DEUBIQUITINASE INHIBITORS | PHARMAKEA, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20160075711-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | MERCK PATENT GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
| US-20160075711-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | MERCK PATENT GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
| WO-2016037026-A1 | CYCLOHEXYL-ETHYL SUBSTITUTED DIAZA- AND TRIAZA-TRICYCLIC COMPOUNDS AS INDOLE-AMINE-2,3-DIOXYGENASE (IDO) ANTAGONISTS FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016037026-A1 | CYCLOHEXYL-ETHYL SUBSTITUTED DIAZA- AND TRIAZA-TRICYCLIC COMPOUNDS AS INDOLE-AMINE-2,3-DIOXYGENASE (IDO) ANTAGONISTS FOR THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2016-03-10 | — | — | WO | disclosed |
| WO-2015187427-A1 | DEUBIQUITINASE INHIBITORS | PHARMAKEA, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088520-A1 | DEUBIQUITINASE INHIBITORS | USP30, USP1, USP28 | ERN1 360/4885CYP3A4 4119/4885TSHR 4060/4885 |
| US-20160075711-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | IDO1, IDO2, INMT | ERN1 4195/4885CYP3A4 853/4885TSHR 2357/4885 |
| US-20240124490-A1 | INHIBITORS OF HPK1 AND METHODS OF USE THEREOF | PHKG1, HIPK1, PHKG2 | ERN1 347/4885CYP3A4 3988/4885TSHR 4720/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | ERN1 3674/4885CYP3A4 35/4885TSHR 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.